You are not logged in.

The maximum tolerated dose of walking for people with severe osteoarthritis of the knee: a phase I trial

Wallis, J.A., Webster, K.E., Levinger, P., Singh, P.J., Fong, C. and Taylor, N.F. 2015, The maximum tolerated dose of walking for people with severe osteoarthritis of the knee: a phase I trial, Osteoarthritis and cartilage, vol. 23, no. 8, pp. 1285-1293, doi: 10.1016/j.joca.2015.04.001.

Attached Files
Name Description MIMEType Size Downloads

Title The maximum tolerated dose of walking for people with severe osteoarthritis of the knee: a phase I trial
Author(s) Wallis, J.A.
Webster, K.E.
Levinger, P.
Singh, P.J.
Fong, C.
Taylor, N.F.
Journal name Osteoarthritis and cartilage
Volume number 23
Issue number 8
Start page 1285
End page 1293
Total pages 9
Publisher Elsevier
Place of publication Amsterdam, The Netherlands
Publication date 2015-08
ISSN 1522-9653
Keyword(s) Knee
Maximum tolerated dose of walking
Osteoarthritis
Physical activity
Aged
Aged, 80 and over
Exercise Tolerance
Female
Humans
Male
Middle Aged
Osteoarthritis, Knee
Pain Measurement
Severity of Illness Index
Time Factors
Walking
Summary OBJECTIVE: To determine how much physical activity, in the form of walking, can be safely and feasibly tolerated for people with severe knee osteoarthritis (OA). DESIGN: Phase I dose response trial with escalating walking doses of 10, 20, 35, 50, 70, and 95 min over 1 week, were prescribed non-randomly to people with severe knee OA. The primary stopping rule was a substantial increase in knee pain. The primary outcomes were an estimation of the maximum tolerated dose of walking; and the proportion of people who did not complete the dose for feasibility reasons. The secondary outcomes were pain, stiffness and activity limitation Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). RESULTS: Twenty-four participants (13 women) aged 53-83 years, and average body mass index (BMI) of 34 kg/m(2) (SD 9) were recruited. Three participants were assigned to each dose between 10 and 70 min, and nine participants assigned to the 95-min dose. The trial was stopped at 95 min due to the maximum number of adverse events occurring at this dose. Therefore, the maximum tolerated dose was 70 min. No participant stopped due to reasons related to feasibility. There was a moderate association between dose and increased activity (linear R(2) = 0.31, cubic R(2) = 0.69) and reduced stiffness (linear R(2) = 0.20, cubic R(2) = 0.52), with increased benefits at moderate to higher doses. CONCLUSIONS: There is preliminary evidence that 70 min per week of moderate intensity supervised walking was safe and feasible for people with severe OA of the knee; for higher doses there was a risk of exacerbating knee pain levels.
Language eng
DOI 10.1016/j.joca.2015.04.001
Field of Research 110399 Clinical Sciences not elsewhere classified
1103 Clinical Sciences
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2015, Elsevier
Persistent URL http://hdl.handle.net/10536/DRO/DU:30081337

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 10 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Tue, 19 Jul 2016, 12:38:15 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.